Can $550m in medical debt relief change healthcare access for California communities?
Discover how Undue Medical Debt’s $550 million California relief reshapes healthcare affordability while exposing deeper billing risks.
Features & Analysis
Features & Analysis
Can CalciMedica rescue Auxora after a mortality imbalance threatened its kidney injury trial?
CalciMedica has preserved the clinical future of Auxora after regulators reviewed safety data from the KOURAGE trial, but restarting development is only the beginning of a difficult scientific and financial recovery.
Features & Analysis
Can Sanofi’s CirCLIQ strategy change how anti-CD38 therapies reach patients?
Discover how wearable injectors could reshape multiple myeloma treatment, clinic capacity and the competitive battle between Sarclisa and daratumumab.
Features & Analysis
How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy
Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.
Features & Analysis
Can ICON turn governance repair into renewed momentum for clinical research services?
ICON’s restatement and backlog reset test CRO confidence as pharma sponsors weigh execution risk, trial demand and 2026 recovery signals.
Features & Analysis
A workers’ comp portal may not sound flashy. For orthopaedic care delays, it could matter
Find out how DMOS Orthopaedic Centers’ new workers’ comp portal could speed referrals, reduce delays and improve injury-care coordination.
Features & Analysis
Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms
Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.
Features & Analysis
Can emergency Ebola treatment centers close Africa’s outbreak response gap?
Find out how Samaritan’s Purse’s Ebola treatment deployment in Congo highlights urgent gaps in outbreak readiness and field care.
Features & Analysis
A rare disease policy shift just landed at the WHO. Could it change hemophilia care worldwide?
Find out how the WHO hemophilia resolution could reshape diagnosis, treatment access, prophylaxis and bleeding disorder care worldwide.
Features & Analysis
How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics
Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.